INT80391

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.54
First Reported 1999
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 4
Total Number 5
Disease Relevance 0.12
Pain Relevance 2.36

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

oxidoreductase activity (Cyp2b2) aging (Cyp2b2) endoplasmic reticulum (Cyp2b2)
Anatomy Link Frequency
liver 2
Cyp2b2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
antidepressant 14 99.06 Very High Very High Very High
sSRI 12 98.76 Very High Very High Very High
dexamethasone 1 96.84 Very High Very High Very High
Desipramine 8 94.92 High High
fluoxetine 6 92.80 High High
diclofenac 20 88.44 High High
Endep 2 85.76 High High
Serotonin 2 78.32 Quite High
Bile 1 74.92 Quite High
noradrenaline 2 69.68 Quite High
Disease Link Frequency Relevance Heat
Hepatotoxicity 1 60.96 Quite High
INFLAMMATION 3 58.28 Quite High
Inflammatory Pain 2 50.00 Quite Low
Injury 1 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The inhibitory effects of TADs were modest (K(i) = 62-85 microM), while mirtazapine was a very weak inhibitor of CYP2B activity (K(i) = 286 microM).
Negative_regulation (inhibitor) of CYP2B
1) Confidence 0.54 Published 2008 Journal Pharmacol Rep Section Abstract Doc Link 19211989 Disease Relevance 0 Pain Relevance 0.79
In summary, two different mechanisms of the antidepressant-CYP2B interaction are postulated: 1) a direct inhibition of CYP2B shown in vitro by nefazodone, SSRIs and TADs; 2) in vivo induction of CYP2B produced by prolonged administration of SSRIs and desipramine, which suggests their influence on enzyme regulation.
Negative_regulation (inhibition) of CYP2B associated with desipramine, antidepressant and ssri
2) Confidence 0.54 Published 2008 Journal Pharmacol Rep Section Abstract Doc Link 19211989 Disease Relevance 0 Pain Relevance 0.86
Within 24 h, these changes were accompanied by a rapid decrease in total P450 contents in FCA-treated rat liver and the selective downregulation of specific CYP isoforms, as illustrated by decreased mRNA levels (CYP2B, CYP2CI1, CYP3A1, and CYP2E1), protein contents (CYP2B, CYP2C11, and CYP2E1) or catalytic activities (CYP2C6, CYP2C11, and CYP2E1).
Negative_regulation (decreased) of CYP2B in liver
3) Confidence 0.05 Published 2005 Journal Pharm. Res. Section Body Doc Link 15771231 Disease Relevance 0 Pain Relevance 0
Within 24 h, these changes were accompanied by a rapid decrease in total P450 contents in FCA-treated rat liver and the selective downregulation of specific CYP isoforms, as illustrated by decreased mRNA levels (CYP2B, CYP2CI1, CYP3A1, and CYP2E1), protein contents (CYP2B, CYP2C11, and CYP2E1) or catalytic activities (CYP2C6, CYP2C11, and CYP2E1).
Negative_regulation (decreased) of CYP2B in liver
4) Confidence 0.05 Published 2005 Journal Pharm. Res. Section Body Doc Link 15771231 Disease Relevance 0 Pain Relevance 0
Adduct formation was inhibited by polyclonal antibodies against CYP2B, CYP2C, and CYP3A (40-50% inhibition at 5 mg of IgG/nmol of CYP) but not by an antibody against CYP1A.
Negative_regulation (inhibition) of CYP2B
5) Confidence 0.02 Published 1999 Journal Drug Metab. Dispos. Section Abstract Doc Link 10064567 Disease Relevance 0.12 Pain Relevance 0.71

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox